Functional Skills
Market Research
Financial Due Diligence
Valuation
Primary Research
Market Mapping
Sector Experience
Business Services
Financial Services
Healthcare
Life Sciences & Pharma
Fortune 500
Top Consulting Firms
Experience
Ikena Oncology
Other
Clinical Development
3/2021 - 12/2021
-Drafted, edited, and reviewed protocol (e.g., rationale, unmet need, inclusion/exclusion, safety, study endpoints) for IND submission of lead oncology asset.
-Analyzed competitive landscape to recommend trial design modifications incorporated into development plan.
-Designed and mapped strategy to engage with patient advocacy groups in 2 target indications.
-Analyzed competitive landscape to recommend trial design modifications incorporated into development plan.
-Designed and mapped strategy to engage with patient advocacy groups in 2 target indications.
Blackstone
Finance
Sr. Associate
5/2021 - 8/2021
-Modeled discounted cash flow analyses and revenue forecasts to understand drivers of BXLS returns and target valuations for 1) a ~$1B royalty monetization, 2) a joint venture buyout vehicle, and 3) a $1B product financing.
-Conducted scientific/commercial diligence in therapeutics (oncology, neurology) and diagnostics via secondary research and key opinion leader interviews, presenting to scientific advisory board and investment partnership.
-Conducted scientific/commercial diligence in therapeutics (oncology, neurology) and diagnostics via secondary research and key opinion leader interviews, presenting to scientific advisory board and investment partnership.
Longitude Capital
Finance
Venture Fellow
5/2018 - 10/2018
-Interviewed academic and industry key opinion leaders for deep dive into oncolytic viruses; designed investment framework to evaluate 214 programs in active development, identifying 3 companies for follow-up.
-Created sourcing database of all 4,679 FDA designated orphan drugs, developing a robust and targeted multi-layer methodology filtering out 2 companies of highest priority; initiated outreach to companies of interest.
-Created sourcing database of all 4,679 FDA designated orphan drugs, developing a robust and targeted multi-layer methodology filtering out 2 companies of highest priority; initiated outreach to companies of interest.
Canaan Partners
Finance
Venture Fellow
10/2017 - 5/2018
-Presented an immuno-oncology (I/O) landscape review of all I/O drugs in clinical development, incorporating KOL interviews on future strategies in predictive biomarkers, combination therapies, and preclinical models.
-Delivered competitive analysis for eventual $14M Series A of an emerging oncology treatment modality.
-Evaluated 22 potential indications for an asset’s growth potential; presented findings to a potential syndicate.
-Delivered competitive analysis for eventual $14M Series A of an emerging oncology treatment modality.
-Evaluated 22 potential indications for an asset’s growth potential; presented findings to a potential syndicate.
Dana Farber Cancer Institute
Research
Clinical Research Coordinator
7/2015 - 4/2017
-Managed 17+ clinical trials in head/neck, thyroid, and Merkel cell carcinoma, including Phase I, II, and III trials; screened and enrolled 80+ cancer patients onto clinical trials.
-Coordinated trials among physicians, patients, nurses, pharmacists, and laboratories to provide investigational drugs to 10+ patients/week, guiding patients through treatment protocols and requirements.
-Maintained regulatory compliance with FDA, pharmaceutical companies, and contract research organizations.
-Coordinated trials among physicians, patients, nurses, pharmacists, and laboratories to provide investigational drugs to 10+ patients/week, guiding patients through treatment protocols and requirements.
-Maintained regulatory compliance with FDA, pharmaceutical companies, and contract research organizations.
Simon-Kucher & Partners
Management Consulting
Life Science Consultant
6/2014 - 8/2014
•Conducted 20+ qualitative interviews with oncologists, pharmacists, and payers in launch price strategy projects for 2 Fortune 500 pharmaceutical companies, followed by data analysis and interpretation of 90+ interviews from 6 countries; collaborated with a team of 5 to structure and build the 2 final recommendations.
•Mined literature to assess current environment of an emergent drug as part of a winning proposal for an oncology drug-price project with a Global 500 pharmaceutical company.
•Mined literature to assess current environment of an emergent drug as part of a winning proposal for an oncology drug-price project with a Global 500 pharmaceutical company.